<DOC>
	<DOCNO>NCT00195078</DOCNO>
	<brief_summary>The purpose study find whether add ZD1839 standard treatment ( Cisplatin Radiation Therapy ) unresectable head neck cancer well cisplatin radiation alone .</brief_summary>
	<brief_title>Safety Trial IRESSA , Cisplatin Radiation Therapy Patients With Head Neck Cancer</brief_title>
	<detailed_description>This Phase I-II , open-label , dose-escalation study subject advance head neck cancer . Subjects receive daily ZD1839 course standard radiation therapy accompany cisplatin . Subjects adults Stage III-IV squamous cell carcinoma oral cavity , oropharynx , larynx , hypopharynx , medically stable condition , Eastern Cooperative Oncology Group ( ECOG ) Performance Status Â£ 1 , stable hepatic bone marrow function , life expectancy least 6 month . Subjects previous cancer history ( exception squamous cell carcinoma skin cervical cancer situ ) prior treatment radiation , chemotherapy , definitive surgical therapy . Subjects Phase II portion trial must measurable disease define RECIST criterion .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm squamous cell carcinoma oral cavity , oropharynx , larynx , hypopharynx . For Phase II portion study : measurable disease base RECIST criterion . Stage III IV disease , M0 . Life expectancy &gt; 6 month . Known severe hypersensitivity ZD1839 excipients product . Other coexist malignancy malignancy diagnose within last 5 year , exception squamous cell carcinoma skin cervical cancer situ . Previous treatment radiation , chemotherapy , definitive surgical therapy . Distant metastatic disease . Documented evidence HIV infection ( interaction ZD1839 Highly Active AntiRetroviral Therapy [ HAART ] unknown ) . Substance abuse psychiatric problem would interfere compliance . Pregnancy breastfeeding ( woman childbearing potential ) . Treatment nonapproved investigational drug within 30 day Day 1 study treatment . Any evidence clinically active interstitial lung disease ( patient chronic stable radiographic change asymptomatic need exclude )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>squamous cell carcinoma oral cavity</keyword>
	<keyword>squamous cell carcinoma oropharynx</keyword>
	<keyword>squamous cell carcinoma larynx</keyword>
	<keyword>squamous cell carcinoma hypopharynx</keyword>
</DOC>